Oliver Herrmann

Aachen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Quality of Life and Patient Satisfaction After the Provision of an Orthopedic Knee Scooter.

Quality of Life and Patient Satisfaction After the Provision of an Orthopedic Knee Scooter.

Journal: Deutsches Arzteblatt international

Published: October 26, 2023

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

Journal: Molecular carcinogenesis

Published: July 22, 2019

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.

Journal: Leukemia

Published: July 09, 2018

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.

Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.

Journal: BMC cancer

Published: April 26, 2018

Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion.

Mtss1(CSC156) mutant mice fail to display efficient Mtss1 protein depletion.

Journal: Leukemia

Published: February 08, 2017

Tumor Suppressor Analysis in CML.

Tumor Suppressor Analysis in CML.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: September 02, 2016

Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Mtss1 is a critical epigenetically regulated tumor suppressor in CML.

Journal: Leukemia

Published: July 23, 2015

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.

Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.

Journal: Leukemia

Published: September 11, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026